Dainippon Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.The original Dainippon Pharmaceuticals was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku .Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical . Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma. As a result Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014. Wikipedia.
Intercept Pharmaceuticals and Dainippon Sumitomo | Date: 2016-04-26
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Sapporo Medical University and Dainippon Sumitomo | Date: 2017-01-18
A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
Dainippon Sumitomo | Date: 2016-12-30
The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R^(1a), R^(1b), R^(1c )and R^(1d )are hydrogen, halogen, cyano, C_(1-4 )alkyl, C_(1-4 )alkoxy, or the like, provided that at least one of R^(1a), R^(1b), R^(1c )and R^(1d )is C_(6-10 )aryl, C_(6-10 )aryloxy, or the like, R^(2 )and R^(3 )are hydrogen, C_(1-6 )alkyl, C_(3-10 )cycloalkyl, or the like, R^(4 )is hydrogen, C_(1-6 )alkyl, C_(3-7 )cycloalkyl, or the like, m is 1, 2 or 3, L is CR^(7)R^(8), and R^(7 )and R^(8 )are hydrogen, hydroxyl, C_(1-4 )alkyl, C_(1-4 )alkoxy, or the like.
Dainippon Sumitomo | Date: 2017-02-27
The present invention provides a 1,4-disubstituted imidazole derivative of formula (1) wherein ring Q^(1 )is optionally-substituted C_(6-10 )aryl group, etc.; R^(1 )and R^(2 )are independently hydrogen atom, etc.; W^(1 )is optionally-substituted C_(1-4 )alkylene group; W^(2 )is NR^(3a)C(O) wherein R^(3a )is hydrogen atom or C_(1-6 )alkyl group, etc.; ring Q^(2 )is 5- to 10-membered heteroaryl group, etc.; W^(3 )is optionally-substituted C_(1-4 )alkylene group, etc.; n is 1, 2, 3, 4, or 5; R^(4 )is independently halogen atom, optionally-substituted C_(1-6 )alkyl group, etc.; R^(5 )is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
Dainippon Sumitomo | Date: 2017-03-29
The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.
Dainippon Sumitomo | Date: 2017-07-19
The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3-pyrrolidine-1,2,3,5-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure.
Dainippon Sumitomo and Kyoto University | Date: 2015-03-30
The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
Dainippon Sumitomo | Date: 2017-08-02
The present invention provides an injectable pharmaceutical composition containing the following components:(a) one or more kinds of peptides selected from a peptide represented by the formula (1):(b) trehalose or trehalose hydrate, and(c) a pH adjuster.
Dainippon Sumitomo | Date: 2017-04-19
The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT_(2C )antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT_(2C )inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R^(1), R^(2 ), R^(3 )and R^(4 )are independently hydrogen or C_(1-6 )alkyl etc.; R^(5 )is C_(4-7 )alkyl or (CR^(8)R^(9))_(r)-E; R^(6), R^(7), R^(8 )and R^(9 )are independently hydrogen, fluorine or C_(1-6 )alkyl; A is C_(6-10 )aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C_(3-8 )cycloalkyl or C_(6-10 )aryl etc.; L is oxygen, sulfur or NR^(10); n is 1, 2 or 3; R^(10 )is hydrogen or C_(1-6 )alkyl etc.; and X is hydrogen or halogen etc.
Dainippon Sumitomo | Date: 2016-03-04
A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): wherein A is CR^(1E )or a nitrogen atom, XYZ is NCONR^(3A)R^(3B )and the like, R^(1A )to R^(1E )are each independently a hydrogen atom and the like, R^(2A )to R^(2D )are each independently a hydrogen atom and the like, R^(3A )and R^(3B )are each independently an optionally-substituted C_(3-10 )cycloalkyl and the like, and n is 1 or 2or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of 7 nicotinic acetylcholine receptor (7 nAChR).